CUAMC
AVIR icon

China Universal Asset Management Company’s Atea Pharmaceuticals AVIR Stock Holding History

China Universal Asset Management Company’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.2K Sell
12,736
-1,128
-8% -$5.61K ﹤0.01% 452
2026
Q1 		$74.6K Buy
13,864
+1,133
+9% +$5.2K 0.01% 431
2025
Q4 		$45.5K Sell
12,731
-1,179
-8% -$3.75K ﹤0.01% 460
2025
Q3 		$40.3K Sell
13,910
-3,278
-19% -$11.2K ﹤0.01% 443
2025
Q2 		$61.9K Buy
17,188
+246
+1% +$734 0.01% 406
2025
Q1 		$50.7K Sell
16,942
-967
-5% -$3.02K ﹤0.01% 420
2024
Q4 		$60K Buy
17,909
+1,672
+10% +$5.56K 0.01% 440
2024
Q3 		$54.4K Buy
16,237
+6,343
+64% +$23K 0.01% 382
2024
Q2 		$32.7K Sell
9,894
-6,285
-39% -$23.4K ﹤0.01% 378
2024
Q1 		$65.4K Buy
16,179
+6,526
+68% +$25.5K 0.01% 398
2023
Q4 		$29.4K Buy
9,653
+7,514
+351% +$22.8K 0.01% 402
2023
Q3 		$6.42K Buy
2,139
+1,046
+96% +$3.56K ﹤0.01% 374
2023
Q2 		$4.09K Sell
1,093
-36
-3% -$135 ﹤0.01% 386
2023
Q1 		$3.78K Buy
1,129
+283
+33% +$1.15K ﹤0.01% 393
2022
Q4 		$4.07K Buy
846
+66
+8% +$334 ﹤0.01% 318
2022
Q3 		$4K Buy
+780
New +$5.97K ﹤0.01% 289

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

China Universal Asset Management Company's AVIR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Atea Pharmaceuticals (AVIR) stake by 8.1% in Q2 2026, selling an estimated $5.61K and leaving 12,736 shares worth $59.2K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

China Universal Asset Management Company first reported a position in AVIR in Q3 2022 and has held it in 16 quarters since. The position peaked at $74.6K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • China Universal Asset Management Company held 12,736 shares of Atea Pharmaceuticals worth $59.2K as of Q2 2026.
  • China Universal Asset Management Company sold 1,128 Atea Pharmaceuticals shares in Q2 2026, an estimated $5.61K.
  • Atea Pharmaceuticals made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #452 holding.
  • China Universal Asset Management Company first reported a position in Atea Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Atea Pharmaceuticals position peaked at $74.6K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.